Costs and Mortality of Clostridioides difficile Infection in Younger Adults
Author Information
Author(s): Yu Holly MSPH, Alfred Tamuno PhD, Zhou Jingying MA, Judy Jennifer PhD, Olsen Margaret A. PhD, MPH
Primary Institution: Pfizer Inc
Hypothesis
To estimate incidence and healthcare costs and mortality associated with Clostridioides difficile infection (CDI) among adults <65 years old.
Conclusion
Prevention of CDI among adults 18–64 years old may significantly reduce costs and mortality.
Supporting Evidence
- CDI incidence decreased from 217 to 167 cases per 100,000 person-years in 50–64-year-olds from 2015 to 2019.
- Mean healthcare costs were $11,634 higher for CDI+ patients compared to CDI− controls in the 50–64 age group.
- Mortality was significantly higher in CDI+ patients compared to CDI− controls at 12 months follow-up.
Takeaway
Clostridioides difficile infection can make people very sick and cost a lot of money, especially for younger adults. If we can stop these infections, we can save lives and money.
Methodology
Retrospective cohort study using a large claims database to analyze CDI incidence, healthcare costs, and mortality.
Potential Biases
Potential underreporting or misclassification of health outcomes in claims data.
Limitations
Retrospective observational design may lead to bias; results may not fully represent the population due to the use of a commercial claims database.
Participant Demographics
US adults aged 18–64 years, with a focus on commercially insured patients.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website